Cost Management Insights: SG&A Expenses for Biogen Inc. and Alkermes plc

Navigating SG&A Expenses: A Tale of Two Biopharma Giants

In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Over the past decade, Biogen Inc. and Alkermes plc have demonstrated distinct strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen's SG&A expenses have shown a steady increase, peaking at approximately 2.67 billion in 2021, reflecting a 20% rise from 2014. This trend underscores Biogen's commitment to expanding its market presence and operational capabilities.

Conversely, Alkermes plc has experienced a more dramatic increase, with SG&A expenses surging by nearly 245% over the same period, reaching around 690 million in 2023. This significant growth highlights Alkermes' aggressive investment in marketing and administrative functions to bolster its competitive edge. As these companies continue to evolve, their SG&A strategies will remain pivotal in shaping their financial health and market positioning.